

# Precision Oncology

Chairs:  
Prof. Dr. Richard F. Schlenk  
Prof. Dr. Carsten Müller-Tidow

March 6<sup>th</sup>, 2018  
16:00 – 18:00  
DKFZ, Communication Center, Lecture Hall

Please register by 5<sup>th</sup> March  
at the latest.

*For this event, two points for  
continuing education will be given  
by the Landesärztekammer.*

*Within the practical year, the points  
will be recognized in the field of  
internal medicine and surgery.*

**Information and registration:**  
Fortbildungs- und Veranstaltungs-  
organisation des Nationalen Centrums  
für Tumorerkrankungen  
Heidelberg School of Oncology  
Im Neuenheimer Feld 460  
69120 Heidelberg  
Phone +49 (0)6221 566558  
Fax +49 (0)6221 565094  
hso@nct-heidelberg.de

[www.nct-heidelberg.de/anmeldung](http://www.nct-heidelberg.de/anmeldung)

Marketing sponsored by:

Celgene GmbH	750,00 €
Janssen-Cilag	1.500,00 €
Novartis Pharma GmbH	1.000,00 €
Pfizer Pharma GmbH	500,00 €
Roche Pharma AG	800,00 €



NCT

NATIONALES CENTRUM  
FÜR TUMORERKRANKUNGEN  
HEIDELBERG

getragen von:  
Deutsches Krebsforschungszentrum  
Universitätsklinikum Heidelberg  
Thoraxklinik-Heidelberg  
Deutsche Krebshilfe

**Carsten Müller-Tidow**, MD is the Director of the Department for Internal Medicine V, Hematology, Oncology and Rheumatology at the University Hospital of Heidelberg. He studied Medicine in Aachen, Bonn and in the United States. A postdoctoral stay at UCLA in Los Angeles was dedicated to molecular biology and epigenetics research in leukemia. He received training in Internal Medicine and Hematology and Oncology at the University of Münster. Subsequent to a Heisenberg Stipend he became Professor at Medicine at the University of Münster in 2009. From 2014 to 2017, he was Director of the Department of Internal Medicine IV, Hematology and Oncology, and of the Landeszentrum für Zell- und Gentherapie at the University of Halle (Saale). In 2017 he moved to Heidelberg. His current research focuses on leukemogenesis and cancer stem cells with a special focus on translating findings into early phase clinical trials.

**Richard Schlenk** is head of NCT trial center at the National Center for Tumor Diseases (NCT), Heidelberg University Hospital and German Cancer Research Center. He moved to Heidelberg from Ulm in September 2016 to design and develop a cross-entity clinical trials program based on multidimensional tumor characterization. Furthermore he has a long lasting interest in acute myeloid leukemia with particular interest in translational clinical trial approaches.

**Stefan Fröhling** heads the Section "Molecular and Cellular Oncology" in the Department of Translational Oncology and co-directs the MASTER molecular stratification program at NCT Heidelberg. After medical school in Marburg and Heidelberg, he trained in internal medicine, hematology, and medical oncology at Ulm University Hospital, followed by

postdoctoral work at Brigham and Women's Hospital and Harvard Medical School. In 2012, Dr. Fröhling moved to Heidelberg, where he works to bring molecularly based patient stratification and targeted therapies to clinical trials broadly across tumor types.

**Daniel Huebschmann** graduated in mathematics, physics and medicine and is a member of the MD/PhD-program of the University of Heidelberg. He is a resident in pediatric oncology and has been working in bioinformatic algorithm development and Next Generation Sequencing (NGS) data analysis since 2014. His research foci are supervised and unsupervised pattern recognition and their applications to lymphoma biology, defects in DNA repair by homologous recombination and personalized oncology. He also has a strong interest in multi-omics integration.

**Prof. Dr. Richard F. Schlenk**  
National Center for Tumor Diseases, Heidelberg

Acute myeloid leukemia, between standard and targeted treatment approaches

**Prof. Dr. Carsten Müller-Tidow**  
University Medical Center, Dept of Haematology,  
Oncology and Rheumatology, Heidelberg

The Heidelberg Leukemia Program, Translation into the clinic

**Prof. Dr. Stefan Fröhling**  
National Center for Tumor Diseases, Heidelberg

Towards Precision Oncology Through Multidimensional Tumor Characterization:  
The NCT/DKTK MASTER Program

**Dr. Daniel Huebschmann**  
German Cancer Research Center, Heidelberg

Next Generation Sequencing: From variant calls to clinically usable  
mutational signatures

**Prof. Dr. Richard F. Schlenk**  
**Prof. Dr. Stefan Fröhling**

From Molecular Profiling to Cross-Entity Treatment Approaches:  
The NCT PMO Clinical Trials Program